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Background: Filamin C (encoded by the FLNC gene) is essential for sarcomere attachment to 
the plasmatic membrane. Mutations in FLNC have been associated with myofibrillar myopathies, 
and cardiac involvement has been reported in some carriers. Accordingly, since 2012 we have 
included FLNC in the genetic screening of patients with inherited cardiomyopathies and sudden 
death. 
Objective(s): We aimed to demonstrate the association between truncating mutations in FLNC 
and the development of high-risk dilated and arrhythmogenic cardiomyopathies. 
Methods: FLNC was studied by next-generation sequencing in 2,877 patients with inherited 
cardiovascular diseases. We identified a characteristic phenotype in probands with truncating 
mutations in FLNC. Clinical and genetic evaluation of 28 affected families was performed. 
Localization of filamin C in cardiac tissue was analysed in patients with truncating FLNC 
mutations using immunohistochemistry. 
Results: Twenty-three truncating mutations were identified in 28 probands previously diagnosed 
with dilated, arrhythmogenic, or restrictive cardiomyopathies. Truncating FLNC mutations were 
absent in patients with other phenotypes, including 1,078 individuals with hypertrophic 
cardiomyopathy. Fifty-four mutation carriers were identified among 121 screened relatives. The 
phenotype consisted in left ventricular dilatation (68%) and systolic dysfunction (46%), left 
ventricular myocardial fibrosis (67%), inferolateral negative T waves and low voltages on ECG 
(33%), ventricular arrhythmias (82%), and frequent sudden cardiac death (40 cases in 21/28 
families). Clinical skeletal myopathy was not observed. Penetrance was >97% in carriers older 
than 40 years. Truncating mutations in FLNC cosegregated with this phenotype with a dominant 
inheritance pattern (combined LOD score: 9.5). Immunohistochemical stainings of myocardial 
tissue showed no abnormal filamin C aggregates in patients with truncating FLNC mutations. 
Conclusions: Truncating mutations in FLNC cause an overlapping phenotype of dilated and left 
dominant arrhythmogenic cardiomyopathies complicated by frequent premature sudden death. 
Prompt implantation of a cardiac defibrillator should be considered in affected individuals 
harboring truncating mutations in FLNC. 
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Filamins cross-link actin filaments forming a widespread network in cardiac and skeletal 
muscles cells (1). Their principal function is the anchorage of membrane proteins to the 
cytoskeleton (2, 3). Gamma filamin or filamin C is one of the three filamin-related proteins, and 
it is encoded by the FLNC gene (4). Filamin C also binds to several proteins in the Z-disk of the 
sarcomere (5-7). 
Mutations in FLNC were initially related to a particular form of skeletal myofibrillar 
myopathy associated in some cases with a non-specified form of “cardiomyopathy” (8-17). For 
that reason, since 2012 we have included FLNC in the genetic screening of patients with 
inherited cardiomyopathies and sudden death. 
Here we describe a characteristic form of cardiomyopathy caused by truncating mutations 
in FLNC in the absence of clinical skeletal myopathy. The phenotype appears as an overlapping 
of dilated and arrhythmogenic cardiomyopathies, characterized by variable degrees of left 
ventricular dilatation and systolic dysfunction, prominent subepicardial and/or intramyocardial 
fibrosis of the left ventricle, frequent ventricular arrhythmias, and sudden cardiac death. 
Methods 
Patients 
From February 2012 to August 2015, FLNC was evaluated by next-generation 
sequencing in 2,877 patients with different inherited cardiovascular diseases (Online Table 1). 
The phenotypes were those established by each center prior to the genetic study. We identified 
28 unrelated probands with truncating mutations in FLNC. Clinical and genetic familial cascade 
screenings were performed in those cases that agreed. All individuals gave their written consent 
to participate in this study. The project was approved by the different local ethics committees 
(N.O. 43/2009, prot.2161; Code registry for Galician CEIC: 2010/447; Record Nº 251; date 
25/01/2010; PI14/01477, CEIB 2014/0306; 2004067, number of approval: 3358). 
Genetic Studies 
Coding exons and intronic boundaries of 213 genes (Online Table 2) related to inherited 
cardiovascular diseases and sudden death were captured using a custom probe library (SureSelect 
Target Enrichment Kit for Illumina paired-end multiplexed sequencing method; Agilent 
Technologies). Sequencing was performed using the Illumina HiSeq 1500 platform (Illumina, 
USA) with 2x100 base read length following Illumina protocols. Bioinformatics analysis was 
performed by means of a custom pipeline including software such as NovoAlign (Novocraft 
Technologies Sdn Bhd), SAMtools, and BCFtools (Sanger Institute) for variant calling and 
genotyping, and Annovar for variant annotation. Mean coverage for all the evaluated genes 
ranged between 250x and 400x. Read depth of every nucleotide from genes related to the 
referring phenotype was >30x. Those exons that did not fulfil this standard were complementary 
sequenced by the Sanger technique. All exons of FLNC were completely covered (>30x). 
Information regarding frequency in different populations (1,000 Genomes Project, Exome 
Variant Server, Exome Aggregation Consortium) was considered. The allele frequency threshold 
to consider a mutation clinically relevant was ≤0.1%. Pathogenicity of variants was classified 
according to current recommendations (18). 
Those variants considered clinically relevant according to the patient’s phenotype were 
confirmed using Sanger sequencing. There is a pseudogene located 53.6 kilobases downstream 
from the functional FLNC gene, which is 98% homologous to exons 46, 47, and 48. All the 
variants identified in those exons were sequenced using specific primers designed to confirm that 
they corresponded to the real FLNC sequence and not to the pseudogene (19). Cascade genetic 
screening in relatives was performed using Sanger sequencing. 
We considered truncating mutations in FLNC those variants that introduce a premature 
stop codon in the protein’s sequence (nonsense or frameshift) or that could alter the splicing 
process according to the predictions of five in silico tools: MaxEntScan, Splice-Site Finder (SSF), 
HSF, NNSPLICE, and GeneSplicer. All the genetic variants included in the present study were 
predicted to disrupt the protein function. 
Statistical Analysis 
The cumulative probability for the occurrence of sudden death, appropriate defibrillator 
shock, heart failure death, or cardiac transplant was estimated by using the Kaplan-Meier method, 
and factors were compared by using the log-rank (Mantel-Cox) method. Survival was calculated 
from birth. A two-sided p-value <0.05 was considered statistically significant. Statistical 
analyses were performed using IBM SPSS Statistics for Windows, Version 21.0 (Armonk, NY: 
IBM Corp). 
Two-point LOD score was calculated in 23 families using the Superlink-Online SNP tool 
(http://cbl-hapw.cs.technion.ac.il/superlink-snp) with the following settings: disease mutant gene 
frequency=0.001, dominant mode of inheritance, penetrance=99%, θ=0. 
Immunohistochemistry 
In order to analyze the presence of filamin C aggregates as a potential cause of 
myocardial injury, we compared 3 patients with truncating mutations in FLNC (26958-II:1, 
36203-III:3, and 25767-III:1) with 3 control samples. Myocardial samples from patients were 
obtained from necropsy or explanted hearts. Immunohistochemistry analysis using a specific 
antibody against the N-terminal extreme of filamin C was performed. In brief, 5-micron-thick 
sections were obtained from paraffin-embedded tissue blocks from patients with truncating 
FLNC mutations and controls. After rehydration, samples were heated for 15 minutes in the 
microwave oven to induce epitope retrieval in Tris-EDTA Buffer, pH 9.0 and were subsequently 
incubated at room temperature (RT) for 15 minutes to enhance penetration of the antibody. 
Slides were then washed twice in a 0.1% Tween-20 Tris-buffered saline (TBS-T) solution and 
blocked with Avidin/Biotin Blocking reagent according to the manufacturer's protocol (Vector 
Laboratories). After washing with TBS-T and blocking with a 15% goat serum TBS-T solution, 
slides were incubated with rabbit polyclonal anti-filamin C gamma (1:50; MyBiosource, 
MBS2026155) raised against the N-terminal peptide of the protein overnight at 4 ºC. Slides were 
TBS-T-washed and incubated with a HRP goat anti-rabbit secondary antibody for 30 minutes at 
RT. Vectastain ABC kit was used to amplify the signal, and DAB substrate kit was used for 
peroxidase detection (Vector Laboratories, Burlingame, California). Counterstaining with 
hematoxylin was carried out before dehydration and mounting the slides with DPX. Pictures 
were taken with a Nikon 90i microscope at different magnifications. 
Results 
Prevalence of truncating mutations in FLNC 
Twenty-three different truncating mutations in FLNC were identified in 28 unrelated 
probands (Figure 1; Online Table 3 and Table 4). Previous diagnoses were dilated 
cardiomyopathy in 20 patients, arrhythmogenic cardiomyopathy in 7 (all of them with 
predominant left ventricular involvement), and restrictive cardiomyopathy in 1. No pathogenic 
mutations in other genes were identified in any of them. We did not find truncating mutations in 
FLNC among 2,105 individuals with other inherited cardiovascular diseases, including 1,078 
patients with hypertrophic cardiomyopathy (Online Table 1). The prevalence of truncating FLNC 
mutations in this heterogeneous global cohort is low (28 out of 2,877 patients screened= 0.97%). 
However, if we refer to the specific phenotypes where this type of mutations were found, the 
proportion is significantly higher: 20 out of 508 patients with dilated cardiomyopathy (3.9%), 7 
out of 219 patients with arrhythmogenic cardiomyopathy (3.2%), and 1 out of 45 individuals 
with restrictive cardiomyopathy (2.2%). 
Phenotype description of patients with truncating mutations in FLNC 
In total, 149 individuals (28 probands and 121 relatives) were clinically and genetically 
evaluated. Fifty-four relatives (45%) carried the FLNC mutation identified in the proband. 
Cardiac alterations were evidenced in 74% of relatives with the mutation (n=40). Mean age at 
presentation in affected carriers was 41±15 years (range 0.3-71). Eleven (92%) of 12 healthy 
mutation carriers were younger than 40 years at last follow-up (mean 32±16; range 6-72). None 
of the 67 non-carriers was clinically affected. Complete cosegregation of truncating mutations in 
FLNC with a particular cardiac phenotype was observed in 23 families who agreed to be 
investigated (combined LOD score: 9.5) (Online Table 5 and Online Figure 1). 
Table 1 shows the clinical characteristics of carriers of truncating mutations in FLNC. 
Exertional dyspnea and palpitations were the most frequent presentation symptoms. Three 
probands were asymptomatic at the moment of diagnosis and were studied due to family history 
of sudden death. Forty-three percent of the affected relatives with positive genotype were 
asymptomatic and were diagnosed through family screening. 
Most of the probands showed left ventricular dilatation (end-diastolic diameter 61±13 
mm) and systolic dysfunction (ejection fraction 34±13%), which were also frequent among 
relatives (end diastolic diameter 53±9 mm; ejection fraction 52±12%). Structural abnormalities 
in the right ventricle (dilatation, akinesia, dyskinesia, or systolic dysfunction) were observed in 
10 probands (36%). All of them presented left ventricular involvement as well. Five (14%) of the 
36 affected relatives with available information showed mild right ventricular abnormalities. 
Mild hypertrophy (maximal wall thickness ≤14 mm) not fulfilling diagnostic criteria for 
hypertrophic cardiomyopathy was described in 10 carriers (13%). 
Most patients were in sinus rhythm, and cardiac conduction defects were mild and 
uncommon. Negative T waves were frequently seen in left precordial (12%), inferior (6%), left 
and inferior (9%), or left and right precordial leads (4%), while no patient presented isolated 
negative T waves in right precordial leads. Low QRS voltages in the limb leads were found in 
25% of mutation carriers (Online Figure 2). Terminal QRS duration >55 ms in leads V1-V3 was 
recorded in 18% of carriers evaluated. No individuals showed epsilon waves. Signal average 
ECG was positive in four of six individuals tested. 
Ventricular arrhythmias were extremely frequent among carriers (82%). Frequent 
ventricular extrasystoles (>500/24 hours) and non-sustained ventricular tachycardia were the 
most common. Sustained ventricular tachycardia was recorded in 10 out of 55 carriers with 
available information, in 3 of them during exercise. 
Electrophysiological study was performed in 8 patients, and ventricular arrhythmias were 
induced in 4 (two non-sustained ventricular tachycardias, one ventricular tachycardia, and one 
ventricular fibrillation). 
The presence of myocardial fibrosis was assessed by magnetic resonance in 15 probands; 
11 of them presented areas with late-gadolinium enhancement exclusively affecting the left 
ventricular wall. Two of these subjects died suddenly (ages 22 and 25, respectively), and fibrosis 
was confirmed on cardiac histology (Figure 2A-B). Three out of 13 probands without magnetic 
resonance study showed myocardial fibrosis confined to the left ventricle on necropsy/explanted 
heart (one died suddenly at age 17, and the other two were transplanted at ages 1 and 60, 
respectively) (Figure 2C-D). Endomyocardial biopsy of the right ventricle revealed large 
amounts of fibrosis in the proband diagnosed with restrictive cardiomyopathy. Globally, 75% of 
those investigated probands developed cardiac fibrosis predominantly affecting the left 
ventricular wall. Among relatives with the mutation, 16 of 31 evaluated relatives (52%) showed 
significant amounts of myocardial fibrosis mainly affecting the left ventricle on magnetic 
resonance (n=13) or in the necropsy (n=2); one relative showed fibrosis on endomyocardial 
biopsy of the right ventricle. Left ventricular myocardial fibrosis was mainly subepicardial. A 
concentric pattern and extension to intramyocardial or transmural involvement was observed in 
some cases. Two patients who were transplanted due to advanced heart failure showed 
endomyocardial fibrosis. 
At initial evaluation no patient suffered from muscle weakness nor showed signs of 
skeletal myopathy. Mild elevation of plasmatic creatine-kinase levels (less than two-fold of 
upper normal value) was found in only 3 out of 40 evaluated carriers. Only one of them (proband 
from family 31277) presented muscle weakness in the lower limbs during follow-up. This patient 
had been diagnosed of restrictive cardiomyopathy aged 29 and had received a cardiac transplant 
aged 45. An electromyography study at age 59 revealed moderate myopathic changes. However, 
this woman was under therapy with simvastatin and corticosteroids that could explain these 
findings. 
Palmoplantar keratoderma was observed and cosegregated with the cardiac phenotype 
and the FLNC mutation (c.4127+1delG) in 4 members from family 29876 (Online Figures 1 and 
3). This finding was not observed in other families from this series. 
Events 
Twelve carriers suffered cardiac arrest (mean age at event 42±16 years; range 17-68), 
being the first manifestation of the disease in 4 of them. All subjects with available data 
presented left ventricular systolic dysfunction (n=9; mean left ventricular ejection fraction: 
39.6±12%; range 21-54) and myocardial fibrosis confined to the left ventricle (n=7). Ventricular 
arrhythmias had been investigated prior to the event in 6 of these 12 individuals, and all of them 
showed frequent ventricular extrasystoles and/or non-sustained ventricular tachycardia. 
Twenty-six affected mutation carriers received or were recommended to have a cardiac 
defibrillator implanted. The indication was primary prevention in 17 (1 declined the indication 
and 1 died suddenly waiting for the implant) and secondary prevention in 9, after suffering a 
symptomatic sustained ventricular tachycardia (n=7) or after an aborted cardiac arrest (n=2); all 
of them exhibited left ventricular systolic dysfunction. Appropriate shocks were recorded in 3/15 
(20%) primary prevention patients and in 5/9 (56%) secondary prevention cases (mean time to 
shock 53±39 months; range 0.1-96) (Online Figure 4). 
Five carriers underwent heart transplantation due to markedly reduced ejection fraction 
(n=4) or restrictive filling with severe pulmonary hypertension (n=1). Mean age at 
transplantation was 43±24 years (range 1-60). 
Considering both carriers (n=12) and affected relatives without genetic study (n=28), 
there have been 40 sudden deaths in 21 of the 28 evaluated families. Mean age at event was 
44±17 years (range: 15-80); 65% occurred in individuals ≤50 years old. Figure 3 shows the 
survival curve for sudden death/appropriate defibrillator shock/heart failure death/heart 
transplant in clinically or genetically affected individuals. 
Immunohistochemistry 
Immunohistochemical stainings of myocardial tissue from patients carrying truncating 
mutations in FLNC showed no abnormal filamin C aggregates in the cytoplasm. In contrast, we 
observed that antibodies against filamin C stained the intercalated disk region in both patients 
and controls (Figure 4). 
Discussion 
We describe the association of truncating mutations in FLNC with a particular 
overlapping phenotype of dilated and left dominant arrhythmogenic cardiomyopathies 
complicated by frequent premature sudden death. Cosegregation of truncating FLNC mutations 
with this phenotype with a dominant mode of transmission was clearly demonstrated in this 
international series of 28 families. Mutation penetrance was >97% in carriers older than 40 years. 
Carriers developed ventricular dilatation with reduced ejection fraction, especially 
affecting the left ventricle. The majority of the affected carriers had been diagnosed with dilated 
cardiomyopathy. However, a significant number of patients had been diagnosed with left-
dominant arrhythmogenic cardiomyopathy. Diagnosis of arrhythmogenic cardiomyopathy is 
challenging and based on multicategorical criteria (20). Left-dominant arrhythmogenic 
cardiomyopathy mimics idiopathic dilated cardiomyopathy, and its clinical diagnostic criteria 
have not been formally established. Many authors have suggested that ventricular arrhythmias 
coming from a fibrotic left ventricular wall in the absence of right ventricular involvement could 
be an expression of left-dominant arrhythmogenic cardiomyopathy (21-23). This phenotype 
frequently presents with inferolateral negative T waves, mild-to-moderate left ventricular 
systolic dysfunction, and regional dyskinesia, all of them identified in several of our patients. 
These patients with truncating mutations in FLNC share clinical characteristics both of 
desmosomal mutations and of laminopathies and desminopathies. Ventricular arrhythmias, likely 
related to the presence of left ventricular myocardial fibrosis, and a high incidence of sudden 
death may appear in all of them (24, 25). Nevertheless, isolated or predominant right ventricular 
involvement, common in desmosomal mutations, was not observed in our patients. On the other 
hand, cardiac conduction abnormalities were mild and infrequent, while they are common and 
severe in patients with pathogenic lamin A/C, emerin, or desmin mutations (24-26). These 
differences likely reflect the involvement of different pathogenic mechanisms. 
All mutations identified in our work are novel except for c.3791-1G>C. This genetic 
variant has been reported in two patients with dilated cardiomyopathy (27, 28). Similarly to our 
findings, significant ventricular arrhythmia was reported in one of them, and clinical signs of 
skeletal myopathy were absent in both. Segregation studies in the described families were quite 
limited. 
Filamin C protein is widely expressed in cardiac myocytes and participates in mechanical, 
sensory, and signal transduction between sarcomeres and plasmatic membranes (2-4). Its 
participation in the attachment of the sarcomere´s Z-disk to the sarcolemma (costameres) and to 
the intercalated disks allows for cell-to-cell mechanical force transduction (7). Filamin C directly 
interacts with two protein complexes that link the subsarcolemmal actin cytoskeleton to the 
extracellular matrix: the dystrophin-associated glycoprotein and the integrin complexes (6). At 
intercalated disks, filamin C is located in the fascia adherens where myofiber ends reach the 
sarcolemma, adjacent to the position of desmosomal junctions (Figure 5) (29). 
Several mutations in FLNC have been previously associated with a particular form of 
myofibrillar myopathy (8-17). This phenotype is mainly characterized by late-onset (usually 
starting in the fourth decade of life) skeletal myopathy, which usually initially involves proximal 
and later distal limb muscles. Cardiac involvement has been described in some patients, with 
approximately 30% of carriers showing a non-specific and poorly characterized cardiomyopathy 
(9). History of early sudden death has been described in these families, but previous publications 
did not provide details about these findings (8-17). Mutations in FLNC previously identified in 
myofibrillar myopathy are mostly missense and in-frame indels. Only two truncating mutations 
were reported in those patients: a nonsense variant close to the C-terminal end of the protein and 
a frameshift variant producing a stop codon in exon 30 (8, 13). Abnormal cytoplasmic filamin C 
aggregates were demonstrated to play a pathogenic role in most of these cases. 
Immunohistochemical analysis showed normal filamin C staining in intercalated disks. 
The absence of abnormal filamin C aggregates in the cardiomyocytes’ cytoplasm of our patients 
with truncating FLNC mutations suggests that the mechanism involved in this type of mutations 
is different from that previously associated with myofibrillar myopathy. One potential 
explanation is that truncating mutations in FLNC would decrease the level of normal filamin C 
by means of haploinsufficiency. This alteration could affect mechanical force transduction at 
intercalated disks and costameres by weakening the binding of the Z-disk to the plasmatic 
membrane. Tissues exposed to high mechanical force generation, such as the left ventricular 
myocardium, could be particularly affected. Myocardial fibrosis, together with dilatation and 
systolic dysfunction of the left ventricle, could be the consequences of this functional alteration. 
In a previous study, a medaka fish harboring a homozygous nonsense mutation in FLNC showed 
early rupture of the myocardial ventricular wall and progressive skeletal muscle degeneration in 
late embryonic stages. The mutant embryo fish showed fewer sarcomere bundles attached to the 
intercalated disks and detachment of myofibrils from sarcolemma and intercalated disks, with 
focal Z-disk destruction (30). 
Clinical signs of skeletal myopathy were specifically and systematically investigated 
among carriers. It is noteworthy that only one of the carriers in our series showed clinical signs 
of skeletal myopathy. Although skeletal biopsies were not performed, creatine-kinase levels were 
within the normal limits in almost all carriers who were investigated. Previous studies suggested 
that skeletal myopathy would be the main phenotype associated with pathogenic FLNC 
mutations. Our data show that cardiac disease would be the main consequence of truncating 
mutations in this gene. Since most previous publications focused on skeletal myopathy and 
cardiac examinations were not routinely performed, subtle cardiac abnormalities only detectable 
through Holter ECG and cardiac magnetic resonance could have been missed.  
It has been suggested that mutations in FLNC could explain nearly 10% of cases of 
hypertrophic cardiomyopathy in patients without mutations in the main sarcomeric genes (31). 
Seven out of eight novel mutations identified in this work were missense variants. In line with 
our results, none of the carriers showed symptoms of skeletal myopathy. Moreover, muscle 
biopsies performed in two patients showed normal histology and histochemistry. It is noteworthy 
that in this report, patients with FLNC mutations showed lower left ventricular wall thickness 
than patients without mutations in FLNC. In fact, 65% of carriers who developed hypertrophy 
showed a maximal wall thickness ≤15 mm. Whether missense mutations lead to hypertrophic 
cardiomyopathy and truncating mutations to dilated/left dominant arrhythmogenic 
cardiomyopathies would need to be confirmed in future studies, but so far we have not identified 
any truncating FLNC mutation in more than 1,000 patients with hypertrophic cardiomyopathy. 
Our data clearly suggest that truncating FLNC mutations are not related to the development of 
hypertrophic cardiomyopathy. 
Two novel missense mutations in FLNC have recently showed cosegregation with 
restrictive cardiomyopathy in two Caucasian families (32). We postulate that the molecular 
mechanism associated with these missense mutations could be different to truncating mutations. 
However, some clinical characteristics of these two families resemble our findings. Several 
carriers showed different amounts of myocardial fibrosis on cardiac histology. Moreover, some 
cases presented T wave abnormalities on ECG or left ventricular systolic dysfunction on 
echocardiogram. Unfortunately, the assessment of ventricular arrhythmias on Holter ECG and 
the evaluation of areas with late-gadolinium enhancement with cardiac magnetic resonance were 
not reported. 
Conclusions 
Truncating mutations in FLNC are associated with a characteristic cardiac phenotype that 
includes left ventricular dilatation with systolic dysfunction and myocardial fibrosis. Ventricular 
arrhythmias are extremely frequent, and families with these mutations show a high incidence of 
sudden cardiac death. We did not find evidence of skeletal myopathy in our series, suggesting a 
new and exclusive cardiac phenotype associated with this type of mutations. 
FLNC should be systematically included in the genetic studies of patients diagnosed with 
dilated, arrhythmogenic, or restrictive cardiomyopathies. The identification of pathogenic 
truncating mutations should prompt a thorough clinical evaluation that should include magnetic 
resonance imaging and Holter ECG monitoring. Implantable defibrillators should probably be 
considered even in cases with only moderate systolic dysfunction in the presence of myocardial 
fibrosis and ventricular arrhythmias.  
  
Perspectives 
Competency in Medical Knowledge 1: Truncating mutations in FLNC cause a particular 
overlapping phenotype of dilated and arrhythmogenic cardiomyopathies. 
Competency in Medical Knowledge 2: The presence of a truncating FLNC mutation should be 
suspected when a cardiomyopathy is characterized by left ventricular systolic dysfunction and/or 
dilatation (could be mild), myocardial fibrosis preferentially affecting the left ventricle, high 
burden of ventricular arrhythmia, and family history of sudden death. 
Competency in Medical Knowledge 3: Mutations in FLNC have been originally and mainly 
related with skeletal myopathy. We demonstrate that truncating mutations in FLNC could lead to 
the development of cardiomyopathy in the absence of clinical skeletal affection. 
Competency in Patient Care 1: Screening for FLNC mutations should be considered in genetic 
testing of patients with dilated, arrhythmogenic, and restrictive cardiomyopathies. 
Competency in Patient Care 2: Clinical assessment of truncating FLNC mutation carriers 
should include cardiac MRI (to rule out myocardial fibrosis), Holter ECG, and stress test (to 
analyze the presence of ventricular arrhythmias).  
Competency in Patient Care 3: Implantation of a cardiac defibrillator could be considered in 
those carriers with myocardial fibrosis and ventricular arrhythmias even if left ventricular 
systolic function is not severely affected. 
Translational Outlook: Carriers of truncating mutations in FLNC showed no abnormal filamin 
C aggregates in myocardial tissue. Further studies are needed to assess the specific functional 
mechanism associated to truncating FLNC mutations. 
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Figure Legends 
Central Illustration. Truncating FLNC mutations causing dilated and arrhythmogenic 
cardiomyopathies. Truncating FLNC mutations could alter intercalated disks and costameres, 
weakening the attachment of myocytes. The consequence is a particular form of cardiomyopathy 
mainly characterized by left ventricular dilatation and systolic dysfunction, myocardial fibrosis 
predominantly affecting the left ventricle, and a high burden of ventricular arrhythmias that leads 
to sudden cardiac death. 
 
Figure 1. Spatial distribution of truncating mutations in filamin C protein. Mutations 
affecting coding exonic regions are showed above the diagram; mutations affecting intronic 
canonical splicing sites are showed below the diagram. CH1= calponin homology domain 1. 
CH2= calponin homology domain 2. Boxes with numbers represent the 24 immunoglobulin-like 
repeats of filamin C. (#)= mutations identified in two unrelated families. 
 
Figure 2. Left ventricular myocardial fibrosis observed in two carriers of truncating FLNC 
mutations. Top images belong to the proband of family 32406, who died suddenly playing 
soccer at age 22: necropsy showing circumferential subepicardial fibrosis (arrows) of the left 
ventricle (Panel A) on the same localization as late-gadolinium enhancement (arrows) detected 
on cardiac magnetic resonance performed prior to death (Panel B). Images on the bottom are 
from the proband of family 26958, who died suddenly at age 17 after a soccer match: 
circumferential left ventricular intramyocardial fibrosis (arrows) on necropsy (Panel A); 
myocardial fibrosis (light blue) affecting the anterior wall of the left ventricle (Masson’s 
trichrome, 2x) (Panel B).  
 
Figure 3. Kaplan–Meier estimates of major cardiovascular events in families with 
truncating FLNC mutations. Survival curves free of sudden death/appropriate defibrillator 
shock/heart failure death/heart transplant in all clinically or genetically affected individuals 
(Panel A) and discriminated by sex (Panel B). 
 
Figure 4. Filamin C localization in cardiac tissue of patients. Immunohistochemical staining 
shows the presence of filamin C only in intercalated disks of controls (Panels A to C) and 
patients with truncating FLNC mutations (Panels D to E). Hematoxylin counterstain was used to 
detect cell nuclei. Scale bar 100μm. 
 
Figure 5. Cellular interactions of filamin C. Cardiomyocytes bind to each other at their 
longitudinal extremes by means of intercalated disks (Panel A). Filamin C directly interacts with 
components of the fascia adherens, allowing for the attachment of Z-disk components to the 
intercalated disks. Filamin C is also localized at costameres that couple the sarcomere to the 
lateral sarcolemma and to the extracellular matrix (Panel B). 
  




Probands (n=28; 17 
males) 
Relatives with the 
mutation (n=54; 28 
males) 
All carriers (n=82; 45 
males) 
  Evaluated 
Positive 
finding % Evaluated 
Positive  




SYMPTOMS               
Asymptomatic 28 3 11 51 30 59 79 33 42 
Dyspnea 28 12 43 51 5 10 79 17 22 
Chest pain 28 4 14 51 3 6 79 7 9 
Muscle weakness 28 0 0 48 0 0 76 0 0 
Syncope 28 4 14 51 7 14 79 11 14 
Palpitations 28 6 21 51 9 18 79 15 19 
Sudden death 28 1 4 51 3 6 79 4 5 
Minor stroke 28 1 4 51 0 0 79 1 1 
ECG               
Sinus rhythm 27 22 81 47 45 96 74 67 91 
Atrial fibrillation 27 4 15 47 2 4 74 6 8 
Pacemaker (atrial) 27 1 4 47 0 0 74 1 1 
Cardiac conduction 
defects (incl. BBB) 27 8 30 47 1 2 74 9 12 
Low voltages 25 9 36 47 9 19 72 18 25 
Negative Tw all 
locations 21 13 62 46 9 20 67 22 33 
Left precordial 
negative Tw 21 6 29 46 2 4 67 8 12 
Right precordial 
negative Tw 21 0 0 46 0 0 67 0 0 
Left + right 
precordial negative 
Tw 21 0 0 46 3 7 67 3 4 
Inferior negative Tw 21 2 10 46 2 4 67 4 6 
Inferior + left 
precordial negative 
Tw 21 4 19 46 2 4 67 6 9 
Inferior + right 
precordial negative 
Tw 21 1 5 46 0 0 67 1 1 
Epsilon wave 21 0 0 46 0 0 67 0 0 
Terminal 
QRS>55ms 20 5 25 45 7 16 65 12 18 
SAECG positive 3 2 67 3 2 67 6 4 67 
CARDIAC 
STRUCTURAL               
AFFECTION 
LV dilatation 27 19 70 47 15 32 74 34 46 
LVEF <55% 27 26 96 49 25 51 76 51 67 
MLVWT ≥ 12mm 27 5 19 50 5 10 77 10 13 
MLVWT ≥ 15 mm 27 0 0 50 0 0 77 0 0 
LV 
hypertrabeculation 27 2 7 47 4 9 74 6 8 
RV 
dilat/akin/dyskin/sys
t dysf 28 10 36 48 5 10 76 15 20 
Myocardium 
fibrosis 20 15 75 31 16 52 51 31 61 
LV fibrosis 19 14 74 30 15 50 49 29 59 
RV fibrosis 20 1 5 31 1 3 51 2 4 
ARRHYTHMIAS               
FVE (>500/24 hs) 23 16 70 32 17 53 55 33 60 
NSVT 23 19 83 32 9 28 55 28 51 
SVT 23 6 26 32 4 13 55 10 18 
Ventricular  
arrhythmia (any) 23 22 96 32 23 72 55 45 82 
EPS positive 3 2 67 5 2 40 8 4 50 
SKELETAL 
MYOPATHY               
Clinical myopathy 28 1 4 48 0 0 76 1 1 
Elevated CK plasma 
levels 21 2 10 19 1 5 40 3 8 
OTHER               
Palmoplantar 
keratoderma 27 1 4 49 3 6 76 4 5 
EVENTS               
Sudden death 28 5 18 54 7 13 82 12 15 
Appropriate ICD 
shock 28 4 14 54 4 7 82 8 10 
Heart failure death 28 0 0 54 0 0 82 0 0 
Heart transplant 28 5 18 54 0 0 82 5 6 
Stroke 28 2 7 54 0 0 82 2 2 
 
BBB= bundle branch block. CK= creatine-kinase. EPS= electro-physiological study. FVE= frequent ventricular 
extrasystoles. ICD= implantable cardioverter defibrillator. LV= left ventricle. LVEF= left ventricular ejection fraction. 
MLVWT= maximal left ventricular wall thickness. NSVT= non-sustained ventricular tachycardia. RV= right ventricle. 
RV dilat/akin/dyskin/syst dysf= right ventricular dilatation, akinesia, dyskinesia, or systolic dysfunction. SAECG: signal-
average ECG. SVT= sustained ventricular tachycardia. Tw= T wave. Terminal QRS>55ms= S wave upstroke of the QRS 
during >55 miliseconds.  
  
